ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Journal and News Scan
This paper looked at the immunotherapy agent Durvalumab used in the perioperative period for resectable NSCLC. A total of 802 patients were enrolled in the study, of which 400 received Durvalumab and the remaining 402 a placebo. The two primary endpoints measured were event-free survival and pathological complete resection. Perioperative Durvalumab plus neoadjuvant chemotherapy, as compared with neoadjuvant chemotherapy alone, was significantly associated with improved results in the two primary endpoints measured. Event-free survival was longer with Durvalumab. The stratified hazard ratio for disease progression, recurrence, or death was 0.68 (p=0.004.) At twelve months, event-free survival was observed with 73.4 percent of Durvalumab patients compared to 64.5 percent of placebo patients. The incidence of pathological complete response was significantly greater with Durvalumab then with placebo (17.2 percent and 4.3 percent respectively, p <0.001). Moreover, a benefit was seen regardless of PD-L1 expression and stage.
In this meta‐analysis, the authors performed a pooled analysis of time‐to‐event data from Kaplan-Meier curves of randomized controlled trials (RCTs) and propensity‐score matched (PSM) studies comparing transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in low-risk patients. The meta-analysis aimed to assess the midterm outcomes of both treatment strategies in low-risk patients. A total of eight studies (three RCTs, five PSM studies) published by December 31, 2022 met the eligibility criteria and included 5,444 patients. 2,639 patients underwent TAVR and 2,805 patients underwent SAVR. In low‐risk patients, TAVR showed a higher risk of all‐cause mortality at eight years of follow up. SAVR was associated with improved survival beyond two years. The survival benefit of SAVR was driven by PSM studies and could not be observed in RCTs. The addition of more extended follow up data from ongoing RCTs will help confirm the possible difference in mid and long term survival between TAVR and SAVR in the low‐risk population.
An official press release from the University of Maryland School of Medicine announced the passing of Mr. Lawrence Faucette, the patient with terminal heart failure who received the world’s second genetically modified pig heart transplant. Mr. Faucette lived for nearly six weeks following the surgery and ultimately succumbed on October 30 due to acute organ rejection despite the initial early success and significant progress after surgery. The medical and scientist team in charge of the xenotransplantation program will conduct an extensive analysis to identify factors that can help to improve the outcome in future xenotransplantation.
The clinical problem addressed in this study is bleeding in patients who undergo ECMO. The authors endeavor to address the issue through a quantitative cohort study by reflecting on how to target the behavior of platelets.
SCTS reported that Dr. Marian Ionescu, a pioneer in cardiac surgery, has passed away. In addition to inventing several artificial heart valves, Dr. Ionescu was a medical educator and established numerous fellowships for cardiothoracic surgeons and allied health professionals.
Bronchial Branching Patterns and Volumetry in the Right Upper Lobe: Impact on Segmentectomy Planning
Segmentectomy is on the rise, but understanding of the segmental bronchial branching pattern is limited. Computed tomography scans of 303 patients were used to determine and categorize the branching of the right upper lobe bronchi. Four major types and eleven subtypes were identified. Volumetry was done to determine the predominant segment in each case. The order of frequency of branching types was trifurcated nondefective (64.4 percent), then bifurcated nondefective (22.1 percent), bifurcated defective (8.6 percent), and trifurcated half-defective (4.0 percent). In 71 percent of cases, one segment was volumetrically predominant, and in 52 percent of all cases this was segment three. There was a higher risk of complex branching in the volumetrically nonpredominant segment and care should be taken during segmentectomy of these segments.
The Society of Thoracic Surgeons (STS) and the European Association of Cardio-Thoracic Surgery (EACTS) published a joint press release regarding aortic valve replacement in low-risk patients. Both associations highlight the value of transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) as outstanding therapeutic options for patients with aortic stenosis and acknowledge the important role of TAVI in high-risk or advanced-age patients.
Furthermore, STS and EACTS welcome randomized controlled trials (RCTs) studying low- and intermediate-risk populations to help inform clinical decision making. Despite the interesting insights of the recently presented and simultaneously published five-year PARTNER 3 and four-year Evolut low-risk trials results, and given the highly selected cohorts and the industry sponsored nature of these trials, both societies consider some equipoise statements as inappropriately weighted. Therefore, STS and EACTS suggest caution in adopting a TAVI-first strategy in low-risk patients, particularly in those patients who differ from the specific cohorts studied in these low-risk trials. Before encouraging a TAVI-first strategy in low-risk patients, more follow-up time from the existing low-risk trials is required.
Finally, STS and EACTS encourage the investigators from both low-risk trials to publish their results for the isolated SAVR and isolated TAVI arms to allow valve therapy specialists to compare low-risk TAVI all-cause mortality outcomes with the real world analysis of patients undergoing low-risk isolated SAVR in the STS Adult Cardiac Surgery Database (Thourani VH, et al., The Annals of Thoracic Surgery, October 2023). Until this data is available, any statements or conclusions from the PARTNER 3 and Evolut Low Risk trials are still hypothesis-generating and speculative.
Surgical tricuspid valve replacement (TVR) is associated with a high risk of postoperative atrioventricular (AV) block. However, placing pacemaker leads through a tricuspid bioprosthesis is discouraged since it might impair bioprosthesis function. Hence, alternative pacing approaches should be considered according to current cardiac pacing guidelines.
This single center retrospective study assessed the benefits and risks of prophylactic epicardial pacemaker implantation during TVR. A total of eighty patients, with a mean age of fifty-seven years, who underwent TVR with concomitant prophylactic epicardial pacemaker implantation were analyzed. TVR was isolated in 28, or 35 percent of patients, but patients with other concomitant procedures were also included. During the postoperative period, with a mean follow-up period of thirty-five months, heart rhythm was analyzed in fifty-nine out of eighty patients. Cardiac pacing was needed in twenty-seven out of fifty-nine, or 46 percent of patients. Eight, or 14 percent, of patients had complete pacing dependency; ten, or 17 percent, of patients had a high degree AV block; nine, or 15 percent, of patients had a high ventricular pacing rate of over 80 percent. A postoperative spontaneous heart rate of over 70 bpm (P = 0.02) and the presence of a narrow QRS-complex (P = 0.03) were identified as predictors of lower cardiac pacing requirement. Epicardial pacemaker implantation was safe, with related complications observed in two, or 2.5 percent of patients.
Given the frequent occurrence of AV block following TVR and the acceptable safety profile, the authors concluded that the prophylactic epicardial pacing strategy in patients undergoing TVR should be considered. The results from this study provide additional information to discuss the need for prophylactic epicardial pacing in patients undergoing tricuspid valve surgery.
This article reviews the benefits of diversity among cardiac surgeons. Specifically, the authors outline the urgent need for redistribution of access and opportunities for women in cardiothoracic surgery and the steps that have been taken to increase equity. Some of these steps include ensuring safety in the profession, providing mentorship, offering educational opportunities, and promoting awareness of implicit bias.
This study determined which measurement—height, weight, BMI, BSA, predicted heart mass, total cardiac volume (TCV)—is most important for assessing donor-recipient heart size mismatch. Amdani and colleagues investigated the Pediatric Heart Transplant Society Database to address this question and identify the effects of donor-recipient size mismatch using a range of parameters. Outcomes were assessed at one and five years of follow up. Interestingly, they report that height and TCV are more relevant to long-term risk of graft loss compared to other metrics.